Cardiology Research and Practice最新文献_第8页

Efficacy of Dialectical Comprehensive Treatment of Traditional Chinese Medicine in Patients with Chronic Stable Heart Failure: A Randomized Controlled Trial 中医辨证综合疗法治疗慢性稳定型心力衰竭的疗效:随机对照试验

IF 2.1 4区医学

Cardiology Research and Practice Pub Date : 2022-05-12 DOI: 10.1155/2022/5408063

Lixiang Yang, Yuanyuan Chen, Fei Lou, Xiaoxia Zhao, Jia Zhou

{"title":"Efficacy of Dialectical Comprehensive Treatment of Traditional Chinese Medicine in Patients with Chronic Stable Heart Failure: A Randomized Controlled Trial","authors":"Lixiang Yang, Yuanyuan Chen, Fei Lou, Xiaoxia Zhao, Jia Zhou","doi":"10.1155/2022/5408063","DOIUrl":"https://doi.org/10.1155/2022/5408063","url":null,"abstract":"The treatment of chronic stable heart failure (CSHF) with integrated traditional Chinese and Western medicine has been of wide concern. We mainly discuss the clinical efficacy of TCM decoction combined with acupuncture and moxibustion (A&M) in CSHF treatment on the basis of syndrome differentiation and treatment (SDT). The control group was given conventional cardiac rehabilitation (CCR), and the treatment group was given TCM decoction combined with A&M treatment based on SDT on the basis of conventional cardiac rehabilitation. The clinical efficacy and cardiopulmonary exercise testing (CPET) indicators were evaluated. Left ventricular ejection fraction (LVEF), NT-proBNP, myocardial ischemia threshold (MIT), and 6-minute walking distance (6MWD) were measured by ultrasound, ELISA, electrocardiogram, and 6MWD test. After treatment, the clinical efficacy, LVEF, and 6MWD of the treatment group were better than in the control group. The NT-proBNP plasma level and MIT in the treatment group were lower than in the control group. The treatment group had enhanced AT, VO2 Peak, VO2 Peak/HR, and Peak power and decreased resting systolic pressure and peak systolic pressure, and the difference was statistically significant. Dialectical comprehensive treatment of TCM could effectively improve cardiac function and clinical treatment effect, which was worthy of clinical application.","PeriodicalId":9494,"journal":{"name":"Cardiology Research and Practice","volume":"65 1","pages":""},"PeriodicalIF":2.1,"publicationDate":"2022-05-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85050774","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Programmed Cell Death of Endothelial Cells in Myocardial Infarction and Its Potential Therapeutic Strategy 心肌梗死中内皮细胞的程序性死亡及其潜在的治疗策略

IF 2.1 4区医学

Cardiology Research and Practice Pub Date : 2022-05-11 DOI: 10.1155/2022/6558060

Mingyue Wu, Zixia Huang, Lijin Zeng, Chunfei Wang, Deming Wang

{"title":"Programmed Cell Death of Endothelial Cells in Myocardial Infarction and Its Potential Therapeutic Strategy","authors":"Mingyue Wu, Zixia Huang, Lijin Zeng, Chunfei Wang, Deming Wang","doi":"10.1155/2022/6558060","DOIUrl":"https://doi.org/10.1155/2022/6558060","url":null,"abstract":"Cardiovascular disease, especially coronary artery disease and stroke, kills around one-third of the world's population, and myocardial infarction, a primary symptom of coronary heart disease, is a major worldwide health problem. Cardiovascular disease research has historically focused on promoting angiogenesis following myocardial damage. Myocardial vascular repair is crucial for improving myocardial infarction prognosis. Endothelial cells, the largest population of nonmyocytes within myocardial tissue, play an important role in angiogenesis. In recent years, different types of programmed cell death such as apoptosis, necroptosis, pyroptosis, ferroptosis, and autophagy have been described and found to be linked with cardiovascular diseases such as myocardial infarction, heart failure, and myocarditis. This will have important implications for reforming the treatment strategy of cardiovascular diseases. Different types of cell death of endothelial cells in myocardial infarction have been proposed, the roles and mechanisms of endothelial cell death in myocardial infarction are summarized in this review, and endothelial cell death inhibition as a therapeutic technique for treating myocardial infarction might be advantageous to human health.","PeriodicalId":9494,"journal":{"name":"Cardiology Research and Practice","volume":"44 1","pages":""},"PeriodicalIF":2.1,"publicationDate":"2022-05-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84073078","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

Pattern Changes in the Heart Rate Variability of Patients Undergoing Coronary Artery Bypass Grafting Surgery 冠状动脉搭桥术患者心率变异性的模式变化

IF 2.1 4区医学

Cardiology Research and Practice Pub Date : 2022-04-30 DOI: 10.1155/2022/1455025

Ngo Van Thanh, Nguyen Sinh Hien, P. N. Son, Pham Truong Son

{"title":"Pattern Changes in the Heart Rate Variability of Patients Undergoing Coronary Artery Bypass Grafting Surgery","authors":"Ngo Van Thanh, Nguyen Sinh Hien, P. N. Son, Pham Truong Son","doi":"10.1155/2022/1455025","DOIUrl":"https://doi.org/10.1155/2022/1455025","url":null,"abstract":"Introduction Coronary artery bypass grafting (CABG) with extracorporeal circulation is a key therapy for coronary artery disease (CAD). However, cardiovascular events and cardiac arrhythmias may still occur in these patients following surgery. Many studies have demonstrated a correlation between cardiac arrhythmias and heart rate variability (HRV). This study aimed to establish the temporal change pattern of HRV observed following CABG. Methods A prospective method was used to study 119 consecutive patients with stable CAD who were assessed using 24-hour Holter recordings 2 days before CABG and 1 week, 3 months, and 6 months after the surgery at Hanoi Heart Hospital from June 2016 to August 2018. Main results: All the time-domain and frequency-domain parameters of HRV decreased precipitately after CABG and were mostly recovered 3 months postoperatively. The percentage of decreased HRV before surgery was 28.6% and 51.8% after 7 days, 19.6% after 3 months, and 12.7% after 6 months. ASDNN and SDNN before and after surgery had the highest rates of change. Conclusion The early decrease in HRV observed 7 days after CABG may be related to the acute effects of the surgery. The recovery of HRV at 3 months after surgery, regardless of the preoperative state of the patients, implies that the autonomic nervous system (ANS) disorder may be improved at this time. At 6 months after surgery, the autonomic nervous injury was recovered in combination with improvement of reperfusion, resulting in improvement in almost all HRV indices compared with those indices preoperatively.","PeriodicalId":9494,"journal":{"name":"Cardiology Research and Practice","volume":"67 1","pages":""},"PeriodicalIF":2.1,"publicationDate":"2022-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73765173","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Analysis of a Family with Brugada Syndrome and Sudden Cardiac Death Caused by a Novel Mutation of SCN5A SCN5A基因突变致Brugada综合征和心源性猝死1家系分析

IF 2.1 4区医学

Cardiology Research and Practice Pub Date : 2022-04-28 DOI: 10.1155/2022/9716045

Yao-Bin Zhu, Jian-Hui Zhang, Yuanling Ji, Ya-Nan Hu, Han-Lu Wang, Dan-dan Ruan, Xiao-Rong Meng, Xin-fu Lin, Jie-wei Luo, W. Chen

{"title":"Analysis of a Family with Brugada Syndrome and Sudden Cardiac Death Caused by a Novel Mutation of SCN5A","authors":"Yao-Bin Zhu, Jian-Hui Zhang, Yuanling Ji, Ya-Nan Hu, Han-Lu Wang, Dan-dan Ruan, Xiao-Rong Meng, Xin-fu Lin, Jie-wei Luo, W. Chen","doi":"10.1155/2022/9716045","DOIUrl":"https://doi.org/10.1155/2022/9716045","url":null,"abstract":"Background Brugada syndrome is a hereditary cardiac disease associated with mutations in ion channel genes. The clinical features include ventricular fibrillation, syncope, and sudden cardiac death. A family with Brugada syndrome with sudden cardiac death was analyzed to locate the associated mutation in the SCN5A gene. Methods and Results Three generations of a Han Chinese family with Brugada syndrome were recruited in the study; their clinical phenotype data were collected and DNA samples extracted from the peripheral blood. Next-generation sequencing was carried out in the proband, and candidate genes and mutations were screened using the full exon capture technique. The family members who participated in the survey were tested for possible mutations using Sanger sequencing. Six family members were diagnosed with Brugada syndrome, including four asymptomatic patients. A newly discovered heterozygous mutation in the proband was located in exon 25 of SCN5A (NM_000335.5) at c.4313dup(p.Trp1439ValfsTer32). Among the surviving family members, only those with a Brugada wave on their electrocardiogram carried the c.4313dup(p.Trp1439ValfsTer32) variant. Bioinformatics prediction revealed that the frameshift of the c.4313dup (p.Trp1439ValfsTer32) mutant led to a coding change of 32 amino acids, followed by a stop codon, resulting in a truncated protein product. Conclusion The newly discovered mutation site c.4313dup(p.Trp1439ValfsTer32) in exon 25 of SCN5A may be the molecular genetic basis of the family with Brugada syndrome.","PeriodicalId":9494,"journal":{"name":"Cardiology Research and Practice","volume":"17 1","pages":""},"PeriodicalIF":2.1,"publicationDate":"2022-04-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85388775","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 3

Association of Low Expression of NUMB in Peripheral Blood with Acute Myocardial Infarction 外周血NUMB低表达与急性心肌梗死的关系

IF 2.1 4区医学

Cardiology Research and Practice Pub Date : 2022-04-26 DOI: 10.1155/2022/7981637

Heyu Meng, Lihong Li, Jianjun Ruan, Yanqiu Chen, Zhaohan Yan, Jinsha Liu, Xiangdong Li, Cuiying Mao, Ping Yang

引用次数: 2

Effect of PCSK9 Inhibitor on Blood Lipid Levels in Patients with High and Very-High CVD Risk: A Systematic Review and Meta-Analysis PCSK9抑制剂对心血管疾病高风险和极高风险患者血脂水平的影响:一项系统综述和荟萃分析

IF 2.1 4区医学

Cardiology Research and Practice Pub Date : 2022-04-26 DOI: 10.1155/2022/8729003

Yue Zhang, Yanrong Suo, Lin-Po Yang, Xiaolu Zhang, Qun Yu, M. Zeng, Wenlan Zhang, Xijuan Jiang, Yijing Wang

{"title":"Effect of PCSK9 Inhibitor on Blood Lipid Levels in Patients with High and Very-High CVD Risk: A Systematic Review and Meta-Analysis","authors":"Yue Zhang, Yanrong Suo, Lin-Po Yang, Xiaolu Zhang, Qun Yu, M. Zeng, Wenlan Zhang, Xijuan Jiang, Yijing Wang","doi":"10.1155/2022/8729003","DOIUrl":"https://doi.org/10.1155/2022/8729003","url":null,"abstract":"Objectives We aimed to investigate the effects of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor on blood lipid levels in patients with high and very-high cardiovascular risk. Design 14 trials (n = 52,586 patients) comparing treatment with or without PCSK9 inhibitors were retrieved from PubMed and Embase updated to 1st Jun 2021. The data quality of included studies was assessed by two independent researchers using the Cochrane systematic review method. All-cause mortality, cardiovascular mortality, and changes in serum low-density lipoprotein cholesterol (LDL-C), total cholesterol (TC), triglyceride (TG), apolipoprotein B (ApoB), lipoprotein (a) (LP (a)), non-high-density lipoprotein cholesterol (non-HDL-C), high-density lipoprotein cholesterol (HDL-C), and apolipoprotein A1 (ApoA1) from baseline were analyzed using Rev Man 5.1.0 software. Results Compared with treatments without PCSK9 inhibitor, addition of PCSK9 inhibitors (evolocumab and alirocumab) had obvious decreasing effects on the levels of LDL-C [MD = −46.86, 95% CI (−54.99 to −38.72), P < 0.00001], TC [MD = −31.92, 95% CI (−39.47 to −24.38), P < 0.00001], TG [MD = −8.13, 95% CI (−10.48 to −5.79), P < 0.00001], LP(a) [MD = −26.69, 95% CI (-27.93 to −25.44), P < 0.00001], non-HDL-C [MD = −42.86, 95% CI (−45.81 to −39.92), P < 0.00001], and ApoB [MD = −38.44, 95% CI (−42.23 to -34.65), P < 0.00001] in high CVD risk patients. Conversely, changes of HDL-C [MD = 6.27, CI (5.17 to 7.36), P < 0.00001] and ApoA1 [MD = 4.33, 95% CI (3.53 to 5.13), P < 0.00001] from baseline were significantly more in high cardiovascular disease risk patients who received PCSK9 inhibitors treatment. Conclusion Addition of PCSK9 inhibitors to standard therapy resulted in definite improvement in blood lipid levels compared with therapies that did not include them.","PeriodicalId":9494,"journal":{"name":"Cardiology Research and Practice","volume":"34 1","pages":""},"PeriodicalIF":2.1,"publicationDate":"2022-04-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88784484","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 7

Impact of MMP-9 Genetic Polymorphism and Concentration on the Development of Coronary Artery Disease in Ukrainian Population MMP-9基因多态性和浓度对乌克兰人群冠状动脉疾病发展的影响

IF 2.1 4区医学

Cardiology Research and Practice Pub Date : 2022-04-11 DOI: 10.1155/2022/2067632

O. Pogorielova, V. Korniienko, Yaroslav D Chumachenko, O. Obukhova, I. Martsovenko, V. Harbuzova

引用次数: 4

Characteristics of Patent Foramen Ovale: Analysis from a Single Center 卵圆孔未闭的特征:单中心分析

IF 2.1 4区医学

Cardiology Research and Practice Pub Date : 2022-04-06 DOI: 10.1155/2022/5430598

Bin Zhang, Dong Li, Anjian Song, Q. Ren, Shangan Cai, Peng Wang, Wenfeng Tan, Gaoxing Zhang, Jun Guo

引用次数: 3

The Effect of Antihypertensive Drugs on NADH in Newly Diagnosed Primary Hypertension 降压药对初诊原发性高血压患者NADH的影响

IF 2.1 4区医学

Cardiology Research and Practice Pub Date : 2022-03-31 DOI: 10.1155/2022/6159883

Regina Pawlak-Chomicka, T. Krauze, P. Uruski, J. Piskorski, A. Wykrętowicz, A. Tykarski, P. Guzik

{"title":"The Effect of Antihypertensive Drugs on NADH in Newly Diagnosed Primary Hypertension","authors":"Regina Pawlak-Chomicka, T. Krauze, P. Uruski, J. Piskorski, A. Wykrętowicz, A. Tykarski, P. Guzik","doi":"10.1155/2022/6159883","DOIUrl":"https://doi.org/10.1155/2022/6159883","url":null,"abstract":"Background Some antihypertensive medications alter cellular energy production, presumably by modification of the mitochondrial function. In vivo studies of such effects are challenging in humans. We applied a noninvasive forearm skin measurement of the 460-nm fluorescence specific for the reduced form of nicotinamide adenine dinucleotide (NADH) to study the 6-week effects of four different antihypertensive medications on mitochondrial function using the Flow-Mediated Skin Fluorescence (FMSF). Methods In a prospective open-label study, we compared the long-term effects of a 6-week treatment with either amlodipine (5 mg), perindopril (5 mg), nebivolol (5 mg), or metoprolol (50 mg) on the dynamic flow-mediated changes in the skin NADH content in 76 patients (29 women) with untreated primary arterial hypertension (HA). Patients underwent 24-hour ambulatory blood pressure monitoring. To study mitochondrial function, the FMSF was measured at rest, during 100-second ischemia and postischemic reperfusion. The control group consisted of 18 healthy people (7 women). Results There were no significant differences in the FMSF parameters between the control and the study group before medication. After the 6-week treatment, all drugs similarly reduced blood pressure. Neither amlodipine, perindopril, nor nebivolol changed the flow-mediated 460-nm skin fluorescence significantly. However, metoprolol raised this fluorescence at rest, during ischemia and reperfusion (P at most <0.05), indicating an increase in the total NADH skin content. Conclusion Amlodipine, perindopril, and nebivolol appear neutral for the skin NADH content during the 6-week antihypertensive treatment. Similar treatment with metoprolol increased skin NADH at rest, during ischemia and reperfusion, probably due to an effect on microcirculation and altered mitochondrial function. Explanation of the potential mechanisms behind metoprolol influence on the skin NADH metabolism requires further investigation.","PeriodicalId":9494,"journal":{"name":"Cardiology Research and Practice","volume":"19 1","pages":""},"PeriodicalIF":2.1,"publicationDate":"2022-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88667488","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 3

Sildenafil for Primary Prevention of Anthracycline-Induced Cardiac Toxicity: A Phase I/II Randomized Clinical Trial, SILDAT-TAHA6 Trial 西地那非用于一级预防蒽环类药物引起的心脏毒性:一项I/II期随机临床试验，SILDAT-TAHA6试验

IF 2.1 4区医学

Cardiology Research and Practice Pub Date : 2022-03-27 DOI: 10.1155/2022/5681510

A. Attar, Masoumeh Heydari, F. Abtahi, A. Rezvani, Shirin Haghighat, R. Vojdani, M. Ramzi, M. Dehghani, M. Karimi, Mohammad Kasaei, S. Khosropanah, M. Tabandeh

{"title":"Sildenafil for Primary Prevention of Anthracycline-Induced Cardiac Toxicity: A Phase I/II Randomized Clinical Trial, SILDAT-TAHA6 Trial","authors":"A. Attar, Masoumeh Heydari, F. Abtahi, A. Rezvani, Shirin Haghighat, R. Vojdani, M. Ramzi, M. Dehghani, M. Karimi, Mohammad Kasaei, S. Khosropanah, M. Tabandeh","doi":"10.1155/2022/5681510","DOIUrl":"https://doi.org/10.1155/2022/5681510","url":null,"abstract":"Background Previous animal studies have shown a protective effect of 5-phosphodiesterase inhibitors on cancer therapeutics-related cardiac dysfunction (CTRCD) of anthracyclines. Aim The aim of this study was to evaluate the clinical effect of sildenafil on the primary prevention of CTRCD in human. Materials and Methods In this randomized double-blind clinical trial, the primary end point was efficacy in preventing the reduction of left ventricular ejection fraction (LVEF). The intervention group patients received sildenafil at a dose of 25 milligrams twice a day before starting the chemotherapeutic regimen, and the control group received placebo. All the patients at baseline and after the 6-month follow-up underwent 4D and speckle-tracking echocardiography and cardiac MRI, accompanied by hs-troponin I and NT-Pro-BNP measurement. Results Sixty patients were enrolled in this study, and data from 52 patients (24 patients in the intervention group and 28 patients in the control group) were used in the final analysis. Our findings showed that in the intervention and control groups, LVEF was dropped from 61.28 ± 7.36 to 51.57 ± 7.67 (difference (D) = −9.71 ± 11.95, p=0.003) and from 57.9 ± 7.29 to 50.2 ± 7.02% (D = −7.7 ± 5.93; p=0.001), respectively (between-group difference = −2.01%, p=0.26). CTRCD was detected in 11 patients in the control group (42.8%) and 10 in the intervention group (41.6%, p=0.51). Conclusion Consumption of sildenafil for primary prevention of anthracycline-induced cardiac toxicity seems to be unbeneficial. This trial is registered with IRCT20180506039554N1.","PeriodicalId":9494,"journal":{"name":"Cardiology Research and Practice","volume":"21 1","pages":""},"PeriodicalIF":2.1,"publicationDate":"2022-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81989582","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0